Phase 2 N=60 Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia.
Hyperuricemia
Primary: Serum Uric Acid<6 mg/dL at Week 4 — 0; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Phase 2 N=10 (+) Epicatechin to Treat Friedreich's Ataxia
Friedreich's Ataxia
Primary: Change From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score — 55.0 score on a scale — p=0.336
Phase 2 N=20 Mexiletine in Sporadic Amyotrophic Lateral Sclerosis
Sporadic Amyotrophic Lateral Sclerosis
Primary: Change in Resting Motor Threshold — -2.430; 0.805; 4.746; 1.465 percentage of maximum stimulus output — p=0.039
Phase 2 N=666 A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=7 Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Number of Participants With Adverse Events Related to AVI-4568 — 0; 0 Participants
Phase 2 N=46 Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
Allergic Rhinitis
Primary: Total Nasal Symptom Score After Nasal Allergen Challenge (NAC) — 3.37; 4.71 score on a scale — p=<0.05
Phase 2 N=14 Amantadine to Speed Awakening After Cardiac Arrest
Coma · Heart Arrest · Anoxia
Primary: Rate of Awakening (Number of Patients Who Are Able to Follow Commands) — 2; 2 Participants
Phase 2 N=49 Enhancement of in-Vitro GC Function in Patients With COPD
COPD
Primary: Sputum Inflammatory Cell Counts — 5.42; 3.89 millions cells/ ml — p=0.012
Phase 2 N=81 Bolus of Saline in Stroke
Ischemic Stroke
Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…
Phase 2 N=26 A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Phase 2 N=10 Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Epistaxis Using the Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Feritin Levels..
Phase 2 N=26 PF-06741086 Multiple Dose Study in Severe Hemophilia
Hemophilia A or B
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 7; 4; 6; 4 Participants
Phase 2 N=64 A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
Celiac Disease
Primary: Percent Change From Baseline in Villous Height to Crypt Depth Ratio (VH:CD) at Week 12 — -62.66; -53.78; -60.17 percent change — p=0.7271
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale